AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39037095 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensionally flexible silicone foam (MFSF) dressings applied preoperatively to face, chest, and iliac crests.
Number of subjects: 48
Study 39037118 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated quick return
Number of subjects: 0
Study 39037118 — intervention group
Group type: COMPARATOR
Intervention: Control (standard shift schedule)
Number of subjects: 0
Study 39037163 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave two-piece pouching system
Number of subjects: 53
Study 39037163 — intervention group
Group type: COMPARATOR
Intervention: Comparator (two-piece pouching system with a flat skin barrier)
Number of subjects: 53
Study 39037513 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Tree (DT) model for UIA instability
Number of subjects: 1376
Study 39037513 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Tree (DT) model incorporating hypertension, aspect ratio, size ratio, bifurcation configuration, and irregular shape
Number of subjects: 1376
Study 39037513 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate Cox analysis
Number of subjects: 1376
Study 39037513 — intervention group
Group type: COMPARATOR
Intervention: Development cohort
Number of subjects: 1376
Study 39037543 — intervention group
Group type: EXPERIMENTAL
Intervention: HR070803 (liposomal irinotecan) in combination with 5-fluorouracil and leucovorin, intravenous infusion from 60 to 80 mg/m²
Number of subjects: 0
Study 39037709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric Oxide (40 ppm) delivered via cardiopulmonary bypass circuit
Number of subjects: 98
Study 39037709 — intervention group
Group type: COMPARATOR
Intervention: Control (no Nitric Oxide)
Number of subjects: 98
Study 39037756 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat Quit Coach (intervention arm)
Number of subjects: 60
Study 39037756 — intervention group
Group type: COMPARATOR
Intervention: Self-help print material (control arm)
Number of subjects: 60
Study 39037762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative statin therapy
Number of subjects: 5592
Study 39037768 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual parent coaching to deliver contingency management for emerging adults (CM-EA)
Number of subjects: 48
Study 39037768 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person peer recovery support services (PRSS) for emerging adults
Number of subjects: 48
Study 39037768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both virtual parent coaching and in-person PRSS
Number of subjects: 48
Study 39037768 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent CM-EA training adherence
Number of subjects: 48
Study 39037768 — intervention group
Group type: EXPERIMENTAL
Intervention: Payers and providers insights
Number of subjects: 48
Study 39037799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs, such as finerenone)
Number of subjects: 0
Study 39037799 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone system inhibitors, statins/nonstatin alternatives, loop diuretics, anticoagulation agents, immunosuppressives, and lifestyle and dietary modifications
Number of subjects: 0
Study 39037799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter-2 inhibitors
Number of subjects: 0
Study 39037800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg of risankizumab (induction trial)
Number of subjects: 975
Study 39037800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (induction trial)
Number of subjects: 975
Study 39037800 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg of risankizumab (maintenance trial)
Number of subjects: 975
Study 39037800 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg of risankizumab (maintenance trial)
Number of subjects: 975
Study 39037800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maintenance trial)
Number of subjects: 975
Study 39037811 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 192
Study 39037811 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 192
Study 39037811 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 192
Study 39037811 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management plus financial incentives
Number of subjects: 192
Study 39037811 — intervention group
Group type: COMPARATOR
Intervention: Financial incentives vs usual care
Number of subjects: 192
Study 39037811 — intervention group
Group type: COMPARATOR
Intervention: Case management plus financial incentives vs usual care
Number of subjects: 192
Study 39037811 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management plus financial incentives vs case management alone
Number of subjects: 192
Study 39037811 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management plus financial incentives vs financial incentives alone
Number of subjects: 192
Study 39037824 — intervention group
Group type: EXPERIMENTAL
Intervention: Difelikefalin; specific dosage and duration not available
Number of subjects: 0
Study 39037824 — intervention group
Group type: COMPARATOR
Intervention: Control group; specific treatment not available
Number of subjects: 0
Study 39037964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib treatment
Number of subjects: 122
Study 39037964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical modeling
Number of subjects: 122
Study 39037976 — intervention group
Group type: EXPERIMENTAL
Intervention: E-MATVR (Enhancing Men's Awareness of Testicular Diseases using Virtual Reality)
Number of subjects: 74
Study 39037976 — intervention group
Group type: COMPARATOR
Intervention: E-MATE (Enhancing Men's Awareness of Testicular Diseases using Electric information)
Number of subjects: 74
Study 39038011 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized sexual dysfunction (SD) screening intervention
Number of subjects: 86
Study 39038096 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical treatment (BMT) plus endovascular treatment (EVT)
Number of subjects: 340
Study 39038096 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 340
Study 39038096 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 340
Study 39038251 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockholm3
Number of subjects: 2129
Study 39038265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus carboplatin and paclitaxel
Number of subjects: 101
Study 39038268 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) followed by high-dose melphalan (200 mg/m2)
Number of subjects: 90
Study 39038282 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health coaching intervention, including asynchronous messages 1-2 times per week, unlimited access to the coach, and monthly videoconference or phone meetings over a 4-month period.
Number of subjects: 103
Study 39038404 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane-based volatile anesthesia
Number of subjects: 118
Study 39038404 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based total intravenous anesthesia
Number of subjects: 118
Study 39038477 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous HIV-1 vaccine regimen (Ad26.Mos4.HIV and clade C gp140)
Number of subjects: 2636
Study 39038477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 2636
Study 39038477 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous HIV-1 vaccine regimen
Number of subjects: 2636
Study 39038479 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (1·0-1·75 mg/kg body weight, subcutaneously, once every 3 weeks)
Number of subjects: 363
Study 39038479 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (450-1050 IU/kg body weight, subcutaneously, once a week; max total dose 80,000 IU)
Number of subjects: 363
Study 39038479 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 363
Study 39038479 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 363
Study 39038700 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (combined aerobic and resistance exercise)
Number of subjects: 50
Study 39038700 — intervention group
Group type: COMPARATOR
Intervention: Active control (flexibility and stretching)
Number of subjects: 50
Study 39038701 — intervention group
Group type: EXPERIMENTAL
Intervention: First-, second-, or third-line systemic therapy for chronic GVHD
Number of subjects: 200
Study 39038815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at week 0, week 4, and every 12 weeks thereafter through week 52.
Number of subjects: 55
Study 39038815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Number of subjects: 55
Study 39038866 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based exercises + video animations
Number of subjects: 132
Study 39038866 — intervention group
Group type: COMPARATOR
Intervention: Paper-based exercises
Number of subjects: 132
Study 39038917 — intervention group
Group type: EXPERIMENTAL
Intervention: IMA202 (autologous genetically modified cytotoxic CD8 T cells)
Number of subjects: 16
Study 39038990 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical menthol (1% menthol applied to hands and feet, two times a day)
Number of subjects: 60
Study 39038990 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study 39039005 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with serratus plane block (group S)
Number of subjects: 80
Study 39039005 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with thoracic epidural (group E)
Number of subjects: 80
Study 39039005 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (group G)
Number of subjects: 80
Study 39039005 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 39039086 — intervention group
Group type: EXPERIMENTAL
Intervention: C-JUN-overexpressing CAR-T cells
Number of subjects: 4
Study 39039292 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endoscopic resection followed by esophagectomy (E group, n=36)
Number of subjects: 334
Study 39039292 — intervention group
Group type: COMPARATOR
Intervention: Esophagectomy alone (S group, n=298)
Number of subjects: 334
Study 39039387 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab IV (450 mg, 900 mg, 1200 mg)
Number of subjects: 50
Study 39039387 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab SC (300 mg, 600 mg)
Number of subjects: 50
Study 39039395 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-Loss Scale
Number of subjects: 21
Study 39039449 — intervention group
Group type: EXPERIMENTAL
Intervention: ABTL0812 (1300 mg tid) combined with carboplatin (AUC 5) and paclitaxel (175 mg/m2)
Number of subjects: 12
Study 39039449 — intervention group
Group type: EXPERIMENTAL
Intervention: ABTL0812 (1300 mg tid)
Number of subjects: 12
Study 39039458 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Behavioral Health Program (CBHP)
Number of subjects: 11
Study 39039488 — intervention group
Group type: EXPERIMENTAL
Intervention: TIME case conferences structured based on cognitive behavioural therapy (CBT)
Number of subjects: 6
Study 39039488 — intervention group
Group type: EXPERIMENTAL
Intervention: TIME case conferences
Number of subjects: 6
Study 39039509 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial carbohydrate-rich nutrition drink (Drink)
Number of subjects: 0
Study 39039509 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight peripheral parenteral nutrition (PPN)
Number of subjects: 0
Study 39039509 — intervention group
Group type: COMPARATOR
Intervention: Isotone Ringer-acetate (Control)
Number of subjects: 0
Study 39039516 — intervention group
Group type: EXPERIMENTAL
Intervention: TCbIP regimen (inetetamab combined with pertuzumab, taxanes, and carboplatin)
Number of subjects: 44
Study 39039516 — intervention group
Group type: COMPARATOR
Intervention: TCbHP regimen (trastuzumab combined with pertuzumab, taxanes, and carboplatin)
Number of subjects: 44
Study 39039548 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 5384
Study 39039548 — intervention group
Group type: COMPARATOR
Intervention: Volatile anesthetics (GAS)
Number of subjects: 5384
Study 39039560 — intervention group
Group type: EXPERIMENTAL
Intervention: E-WORTH intervention (n=172), a 5-session, culturally-tailored, group-based HIV prevention intervention including introduction to PrEP and access.
Number of subjects: 336
Study 39039560 — intervention group
Group type: COMPARATOR
Intervention: HIV testing control group (n=180).
Number of subjects: 336
Study 39039582 — intervention group
Group type: EXPERIMENTAL
Intervention: Real PL and real tES
Number of subjects: 0
Study 39039582 — intervention group
Group type: COMPARATOR
Intervention: Real PL and sham tES
Number of subjects: 0
Study 39039582 — intervention group
Group type: COMPARATOR
Intervention: Placebo PL and sham tES
Number of subjects: 0
Study 39039609 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated management strategies including health worker training, adaptation of HIV EHR for HTN/CVD care, and use of treatment partners
Number of subjects: 290
Study 39039609 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated management strategies
Number of subjects: 290
Study 39039666 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-based immuno-chemotherapy and maintenance
Number of subjects: 299
Study 39039666 — intervention group
Group type: COMPARATOR
Intervention: Pre-vaccination phase
Number of subjects: 299
Study 39039666 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-vaccination phase
Number of subjects: 299
Study 39039666 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 299
Study 39039739 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 180
Study 39039739 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 180
Study 39039739 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) with OAC
Number of subjects: 180
Study 39039739 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM) with OAC
Number of subjects: 180
Study 39039833 — intervention group
Group type: EXPERIMENTAL
Intervention: TFP block (20 ml 0.25% bupivacaine for each side)
Number of subjects: 79
Study 39039833 — intervention group
Group type: COMPARATOR
Intervention: TAP block (20 ml 0.25% bupivacaine for each side)
Number of subjects: 79
Study 39039833 — intervention group
Group type: EXPERIMENTAL
Intervention: TFP block
Number of subjects: 79
Study 39039833 — intervention group
Group type: COMPARATOR
Intervention: TAP block
Number of subjects: 79
Study 39039933 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional chewing gum
Number of subjects: 0
Study 39039933 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39040037 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative care (IC) model including ACS secondary prevention program and depression care (case screening, group counselling, individual problem-solving therapy)
Number of subjects: 4041
Study 39040037 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative care (IC) model
Number of subjects: 4041
Study 39040037 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 4041
Study 39040184 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (2 g/kg) alone
Number of subjects: 134
Study 39040184 — intervention group
Group type: COMPARATOR
Intervention: IVIG (2 g/kg) with high-dose aspirin (80-100 mg/kg/day) until fever subsided for 48 hours, followed by daily aspirin (3-5 mg/kg) for six weeks
Number of subjects: 134
Study 39040578 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg
Number of subjects: 1682
Study 39040578 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg
Number of subjects: 1682
Study 39040578 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1682
Study 39040670 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior® solution
Number of subjects: 180
Study 39040670 — intervention group
Group type: COMPARATOR
Intervention: St Thomas® solution
Number of subjects: 180
Study 39040774 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-STAR (cone beam computed tomography-guided stereotactic adaptive radiotherapy)
Number of subjects: 1
Study 39040844 — intervention group
Group type: EXPERIMENTAL
Intervention: AK-EPQ (Actinic Keratosis Expert Panel Questionnaire)
Number of subjects: 0
Study 39040844 — intervention group
Group type: EXPERIMENTAL
Intervention: AK-EPQ
Number of subjects: 0
Study 39040882 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCHES intervention
Number of subjects: 1492
Study 39040882 — intervention group
Group type: COMPARATOR
Intervention: Control (standard counseling)
Number of subjects: 1492
Study 39040887 — intervention group
Group type: EXPERIMENTAL
Intervention: CVnCoV vaccine
Number of subjects: 0
Study 39040887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 0
Study 39041200 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanzalintinib + Atezolizumab
Number of subjects: 900
Study 39041200 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 900
Study 39041351 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified granulocyte concentrates (GC)
Number of subjects: 0
Study 39041411 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for 6 months with salvage radiotherapy (SRT)
Number of subjects: 534
Study 39041411 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) for 24 months with salvage radiotherapy (SRT)
Number of subjects: 534
Study 39041887 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (Flublok; Sanofi Pasteur)
Number of subjects: 447
Study 39041887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 447
Study 39041933 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased differential stroke volume (greater than 30 mL)
Number of subjects: 4058
Study 39041933 — intervention group
Group type: COMPARATOR
Intervention: Balanced differential stroke volume (greater than or equal to -30 mL to ≤30 mL)
Number of subjects: 4058
Study 39041933 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative differential stroke volume (less than -30 mL)
Number of subjects: 4058
Study 39042017 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hyaluronic acid (HLA)
Number of subjects: 49
Study 39042017 — intervention group
Group type: COMPARATOR
Intervention: Vaginal estrogen
Number of subjects: 49
Study 39042292 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P41 (60 mg subcutaneous)
Number of subjects: 479
Study 39042292 — intervention group
Group type: COMPARATOR
Intervention: US-denosumab
Number of subjects: 479
Study 39042292 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P41
Number of subjects: 479
Study 39042310 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-anastomosis duodeno-ileal bypass (SADI)
Number of subjects: 56
Study 39042310 — intervention group
Group type: COMPARATOR
Intervention: Biliopancreatic diversion with duodenal switch (BPD/DS)
Number of subjects: 56
Study 39042407 — intervention group
Group type: EXPERIMENTAL
Intervention: ZY5301 300 mg/d
Number of subjects: 180
Study 39042407 — intervention group
Group type: EXPERIMENTAL
Intervention: ZY5301 600 mg/d
Number of subjects: 180
Study 39042407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 39042426 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrated digital platform (3-month intervention)
Number of subjects: 295
Study 39042426 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care assessment and addressing of social needs (3-month control)
Number of subjects: 295
Study 39042439 — intervention group
Group type: EXPERIMENTAL
Intervention: MindCotine VR program
Number of subjects: 105
Study 39042613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 bolus (80,000 IU)
Number of subjects: 25
Study 39042770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleselumab combined with tacrolimus and corticosteroids as maintenance immunosuppression
Number of subjects: 63
Study 39042770 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) comprising tacrolimus, mycophenolate mofetil, and corticosteroids
Number of subjects: 63
Study 39042843 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Care at Home (SCH)
Number of subjects: 358
Study 39042843 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 358
Study 39042875 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm designed to guide the deprescribing of drugs for OAB
Number of subjects: 0
Study 39042875 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 39042892 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrant 1 (high pre-HCT AUC ≥50 AU/day/mL, low post-HCT AUC <12 AU/day/L)
Number of subjects: 163
Study 39042892 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrant 2 (low pre- and post-HCT AUC)
Number of subjects: 163
Study 39042892 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrant 3 (low pre-HCT AUC, high post-HCT AUC)
Number of subjects: 163
Study 39042892 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrant 4 (high pre- and post-HCT AUC)
Number of subjects: 163
Study 39043009 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg plus Tremelimumab 3 mg/kg
Number of subjects: 71
Study 39043009 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg plus Tremelimumab 1 mg/kg
Number of subjects: 71
Study 39043009 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg plus Tremelimumab 1 mg/kg (dose expansion cohort)
Number of subjects: 71
Study 39043009 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg plus Tremelimumab 1 mg/kg (dose expansion cohort)
Number of subjects: 71
Study 39043009 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 71
Study 39043009 — intervention group
Group type: EXPERIMENTAL
Intervention: All cohorts
Number of subjects: 71